证券代码：301258 证券简称：富士莱 公告编号：2023-047 苏州富士莱医药股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）第四届监事会第七次会 议于 2023 年 8 月 18 日下午 3 时在公司会议室以现场表决方式召开，会议通知 于 2023 年 8 月 8 日以邮件、电话、书面等方式通知全体监事。会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席召集并主持。会议的召集、召 开及表决程序符合法律法规及《公司章程》的有关规定。 一、议案审议情况 （一）审议通过《2023 年半年度报告全文及其摘要》 监事会认为：公司《2023 年半年度报告》和《2023 年半年度报告摘要》的 编制和审议程序符合相关法律、法规及《公司章程》的规定。内容与格式符合各 项规定，所包含的信息能从各方面真实、准确、完整地反映出公司 2023 年上半 年度经营管理和财务状况等事项。未发现参与公司 2023 年半年度报告编制和审 议的人员有违反保密规定及损害公司利益的行为。监 ...

苏州富士莱医药股份有限公司 独立董事关于第四届董事会第八次会议相关事项的 根据相关法律、法规及规范性文件的规定，我们本着严谨、实事求是的态度 对公司 2023 年半年度关联方资金占用情况进行了认真了解和核查，并作如下专 项说明和独立意见： 经核查，报告期内公司控股股东及其他关联方不存在占用公司资金的情况， 也不存在以前年度发生但延续至报告期的控股股东及其他关联方占用公司资金 情况。 三、关于 2023 年半年度公司对外担保情况的专项说明和独立意见 根据相关法律、法规及规范性文件的规定，我们对报告期内公司对外担保情 况进行了认真了解和核查，并作如下专项说明和独立意见： 经核查，报告期内公司不存在为控股股东及其关联方、其他第三方提供担保 的情况，未发生损害公司及公司股东，尤其是中小股东利益的情况。 独立意见 根据《公司法》、《上市公司独立董事规则》、公司《独立董事工作制度》和 《公司章程》等有关规定，作为苏州富士莱医药股份有限公司（以下简称"公司"） 的独立董事，对公司第四届董事会第八次会议相关事项发表如下独立意见： 一、关于公司 2023 年半年度募集资金存放与使用情况的独立意见 我们认为：2023 年半年度， ...

根据深圳证券交易所《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格 式》的规定，将苏州富士莱医药股份有限公司（以下简称公司）2023 年半年度募集资金 存放与使用情况报告如下： 一、募集资金基本情况 苏州富士莱医药股份有限公司 2023 年半年度募集资金存放与使用情况专项报告 苏州富士莱医药股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意苏州富士莱医药股份有限公司首次公开发行 股票注册的批复》（证监许可〔2022〕251 号）同意注册，公司于 2022 年 3 月向社会公 开发行人民币普通股（A 股）股票 2,292 万股，每股面值人民币 1.00 元，每股发行价为 48.30 元，应募集资金总额为人民币 110,703.60 万元，根据有关规定扣除发行费用（不 含增值税）10,390.10 万元后*1，实际募集资金金额为 100,313.50 万元。该募集资金已于 2022 年 3 月到账。上述资金到账情况业经容诚会计师事 ...

苏州富士莱医药股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：苏州富士莱医药股份有限公司 单位：万元 | | 资金占用方名 | | 占用方与上市公 | 上市公司核算的 | 2023 | 年期初占用 | 2023 年半年度占 | 2023 年半年度占 | 2023 年半年度偿 | 2023 年半年度期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 称 | 司的关联关系 | 会计科目 | | 资金余额 | 用累计发生金额 | 用资金的利息 | 还累计发生金额 | 末占用资金余额 | 占用形成原因 | 占用性质 | | | | | | | | | （不含利息） | （如有） | | | | | | 控股股东、实际控制人及 | | | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | | | 小计 | | - | - | - | | | | | | | | | | 前控股 ...

证券代码：301258 证券简称：富士莱 公告编号：2023-043 苏州富士莱医药股份有限公司（以下简称"公司"）于 2023 年 3 月 14 日召开 第四届董事会第四次会议、第四届监事会第四次会议以及 2023 年 3 月 31 日召开 2023 年第一次临时股东大会，审议通过了《关于使用部分闲置自有资金进行委 托理财的议案》，为提高资金使用效率，在不影响公司正常经营的情况下，同意 公司使用不超过 120,000.00 万元闲置自有资金进行中低风险投资理财。具体内容 详见公司 2023 年 3 月 15 日和 2023 年 3 月 31 日披露于巨潮资讯网 （http://www.cninfo.com.cn）的相关公告。 近期，公司使用部分闲置自有资金进行了委托理财，现将有关情况进展公告 如下： | 序 | 受托方名称 | 产品名称 | 金额（万 | 产品类型 | 产品起息日 | 产品到期日 | 预期年化收益 | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | 元） | | | | 率 | | 1 | 常熟农村商 业银行股份 有限公 ...

证券代码：301258 证券简称：富士莱 公告编号：2023-042 苏州富士莱医药股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公 告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 | 序 | 受托方名称 | 产品名称 | 金额（万 | 产品类型 | 产品起息 | 产品到期 | 预期年化收益 | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | 元） | | 日 | 日 | 率 | | 1 | 苏州银行股 份有限公司 | 2023 年第 2394 期定制结构性存 | 7,000.00 | 保本浮动 收益型产 | 2023-8-7 | 2023-10-29 | 1.7%或 2.75% | | | 常熟支行 | 款 | | 品 | | | 或 2.85% | 一、本次募集资金现金管理的基本情况 二、关联关系 公司与上述受托方不存在关联关系，本次使用部分闲置募集资金进行现金管 理不会构成关联交易。 三、投资风险及风险控制措施 （一）投资风险 苏州富士莱医药股份有限公司（以下简称"公司" ...

Financial Performance - The company's revenue for Q1 2023 was ¥156,494,544.37, representing a 10.38% increase compared to ¥141,779,121.55 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was ¥51,606,248.85, a 29.28% increase from ¥39,919,425.66 year-on-year[5] - The company reported a 34.31% increase in net profit after deducting non-recurring gains and losses, totaling ¥44,794,928.10 compared to ¥33,353,129.22 in the previous year[5] - Total operating revenue for Q1 2023 reached ¥156,494,544.37, an increase of 10.5% compared to ¥141,779,121.55 in the same period last year[21] - The operating profit for Q1 2023 was ¥60,230,108.07, an increase of 29.3% compared to ¥46,518,162.66 in the previous period[22] - The net profit for Q1 2023 reached ¥51,606,248.85, up 29.4% from ¥39,919,425.66 in the same period last year[22] - The total comprehensive income attributable to the parent company was ¥51,606,248.85, an increase from ¥39,919,425.66 in the previous year[22] Cash Flow and Investments - The net cash flow from operating activities reached ¥61,890,371.17, marking a significant increase of 175.78% compared to ¥22,441,786.64 in Q1 2022[5] - Cash flow from operating activities generated a net amount of ¥61,890,371.17, significantly higher than ¥22,441,786.64 in the previous year, marking an increase of 175.5%[24] - Total cash inflow from investment activities was ¥942,927,102.55, compared to ¥31,345,383.92 in the previous period, indicating a substantial increase[24] - The cash flow from investment activities resulted in a net outflow of ¥11,858,460.08, worsening from a net outflow of ¥3,171,032.05 in the previous year[24] - The cash and cash equivalents at the end of Q1 2023 totaled ¥308,972,576.39, down from ¥1,329,798,336.02 at the end of the previous period[24] Assets and Liabilities - The company's total assets as of March 31, 2023, were ¥2,134,702,585.08, up 1.73% from ¥2,098,360,763.12 at the end of the previous year[5] - Total liabilities decreased to ¥196,486,281.73 from ¥211,750,708.62, a reduction of 7.2%[20] - The company reported a decrease in short-term borrowings and a reduction in accounts payable, indicating improved liquidity management[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,558[11] - The largest shareholder, Suzhou Fushilai Technology Service Development Center, holds 60.22% of the shares, totaling 55,200,000 shares[11] - In Q1 2023, the company reported a total cash dividend distribution of RMB 53,168,600, which translates to RMB 5.80 per 10 shares for all shareholders[16] - The total number of shares for the dividend distribution is based on a total share capital of 91,670,000 shares[16] - The company has a total of 68,750,000 restricted shares, with 10,330,000 shares released during the period[15] - The largest unrestricted shareholder is Wujiang Dongfang Guofa Venture Capital Co., Ltd., holding 2,931,900 shares[12] - The company has a total of 55,200,000 restricted shares held by Suzhou Fushilai Technology Service Development Center, locked for 42 months[14] - The company’s shareholder Yang Chang holds 151,600 shares through a margin trading account[12] - The company’s major shareholders include Suzhou Guofa Angel Venture Capital with 1,758,800 shares and Suzhou Longju Chuanlian Venture Capital with 976,700 shares[12] - The company has a total of 350,000 shares held by shareholder Lu Jiangang, locked for 18 months[15] - The company’s shareholder Zhang Weidong holds 647,500 shares, with 1,375,000 shares released on March 29, 2023[15] - The company has a total of 300,000 shares held by shareholder Qian Yi, with 225,000 shares released during the period[15] Expenses and R&D - Total operating costs amounted to ¥105,348,284.97, up from ¥102,613,441.78, reflecting a rise of 2.1% year-over-year[21] - Research and development expenses for the quarter were ¥9,226,220.69, compared to ¥8,771,509.27 in the previous year, showing an increase of 5.2%[21] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[21] Other Financial Metrics - The weighted average return on equity decreased to 2.70% from 5.23% year-on-year[5] - Cash and cash equivalents rose to ¥308,972,576.39 from ¥259,687,908.54, representing a growth of 18.9%[19] - Inventory increased to ¥129,384,336.39 from ¥122,688,096.16, reflecting a rise of 5.5%[19] - The basic and diluted earnings per share for Q1 2023 were both ¥0.56, slightly down from ¥0.58 in the previous period[22] - The company did not report any income from asset disposals during the period[22]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-on-year growth of 15%[12] - The net profit attributable to shareholders was 200 million RMB, an increase of 10% compared to the previous year[12] - The company's operating revenue for 2022 was ¥568,213,343.96, an increase of 8.92% compared to ¥521,695,665.95 in 2021[17] - The net profit attributable to shareholders for 2022 was ¥177,303,662.82, representing a significant increase of 47.51% from ¥120,201,415.72 in 2021[17] - The net profit after deducting non-recurring gains and losses was ¥172,416,638.82, up 49.39% from ¥115,415,204.48 in the previous year[17] - The total assets at the end of 2022 reached ¥2,098,360,763.12, a substantial increase of 116.26% from ¥970,306,076.54 at the end of 2021[17] - The net assets attributable to shareholders increased by 153.97% to ¥1,886,610,054.50 from ¥742,839,394.81 in 2021[17] - The basic earnings per share for 2022 were ¥2.06, reflecting a growth of 17.71% compared to ¥1.75 in 2021[17] - The weighted average return on equity decreased to 11.33% in 2022 from 17.61% in 2021, a decline of 6.28%[17] - The net cash flow from operating activities was ¥151,187,132.90, down 24.30% from ¥199,729,417.14 in 2021[17] Dividend Distribution - The company plans to distribute a cash dividend of 5.80 RMB per 10 shares, totaling approximately 53 million RMB[3] - The company distributed a cash dividend of 4.00 RMB per 10 shares, totaling 36,668,000.00 RMB, based on a total share capital of 91,670,000 shares[130] - The total cash dividend represents 100% of the distributable profit of 604,523,135.61 RMB[133] - No new shares will be issued as part of the dividend distribution, and no capital reserve will be converted into share capital[133] Market Expansion and Strategy - The company has set a revenue target of 1.5 billion RMB for 2023, indicating a growth forecast of 25%[12] - User data showed an increase in active users by 25% year-on-year, reaching 500,000 active users by the end of 2022[12] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[12] - A strategic acquisition of a local biotech firm was completed, enhancing the company's R&D capabilities and product pipeline[12] - The company aims to expand into the CMO/CDMO sectors, providing contract manufacturing and development services to pharmaceutical companies[34] Research and Development - New product development includes the launch of three innovative drugs expected to enter the market in 2023, with projected sales of 300 million RMB[12] - The company holds 41 patents, including 40 invention patents, demonstrating its strong R&D capabilities and innovation[36] - R&D expenses for the year were 41.37 million yuan, a 45.08% increase year-on-year, representing 7.28% of total revenue, marking a historical high for R&D investment intensity[52] - The number of R&D personnel increased by 34.18% to 106 in 2022, with a higher proportion of personnel holding bachelor's degrees (54%)[66] Environmental Compliance - The company has received environmental impact assessment approvals for multiple projects, including a major project for the construction of a research and development center approved on November 21, 2022[141] - The valid pollutant discharge permit issued on December 29, 2021, allows the company to emit volatile organic compounds, particulate matter, sulfur dioxide, nitrogen oxides, toluene, benzene, hydrochloric acid, ammonia, and other pollutants until December 28, 2026[141] - The company has successfully completed environmental protection acceptance for various projects, including the expansion project for the production of 720 tons of pharmaceutical intermediates and raw materials[140] - The company has undergone multiple environmental assessments and approvals since 2010, demonstrating compliance with environmental regulations and standards[140] - The company has a comprehensive environmental management strategy in place, focusing on reducing emissions and optimizing production processes[140] Corporate Governance - The company maintains a complete and independent business system, ensuring no asset or fund occupation by controlling shareholders[104] - The company has established a comprehensive personnel management system, ensuring independence from controlling shareholders in management roles[104] - The company’s governance structure complies with relevant laws and regulations, ensuring orderly management and operation[103] - The company has developed a robust procurement, production, and sales system, maintaining full control over its assets[104] - The company has a clear internal management and control system, tailored to its operational needs[105] Financial Management - The company has a rigorous fundraising management system in place to ensure that raised funds are used effectively for designated projects[175] - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[178] - The company has committed to compensating investors for losses incurred due to fraudulent issuance if such a situation arises[175] - The company has outlined measures to enhance corporate governance and protect the rights of minority shareholders[175] Social Responsibility - The company donated CNY 200,000 to the Changshu Charity Federation and contributed CNY 100,000 to the Nanjing Medical University Education Development Foundation during the reporting period[155] - The company has actively engaged in social responsibility initiatives, including employment support for five disabled individuals[155] Challenges and Risks - The company has faced challenges due to global supply chain disruptions and rising commodity prices, which have affected production and operational costs[45] - Risk management strategies have been outlined to address potential regulatory changes and market volatility, ensuring business continuity[3] Production and Capacity - The company plans to expand its production capacity through fundraising projects, aiming to overcome current capacity bottlenecks and increase market share[42] - The production capacity utilization rate for the alpha-lipoic acid series was 105.24%, indicating strong demand and efficient production[48] - The sales revenue from the alpha-lipoic acid series reached 453.76 million yuan, a year-on-year increase of 10.10%, contributing 79.86% to the main business revenue[54] Investor Relations - The company held a total of 54 investor communication meetings in August 2022, including a conference call on August 23, 2022[100] - The company has been actively engaging with various institutional investors to enhance transparency and communication[100] - The company held multiple shareholder meetings in 2022, with investor participation rates of 75.09%, 74.89%, 65.67%, and 64.06% for the respective meetings[106]

证券代码：301258 证券简称：富士莱 公告编号：2023-023 投资者依据提示，授权登入"富士莱投资者关系"小程序，即可参与交 流。欢迎广大投资者积极参与。 苏州富士莱医药股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日 在巨潮资讯网（www.cninfo.com.cn）上披露了公司《2022 年年度报告》。 为加强与投资者的深入交流，使投资者更加全面、深入地了解公司情况。 公司定于 2023 年 4 月 26 日（星期三）下午 15:00-17:00 在"富士莱投资者关 系"小程序举行 2022 度网上业绩说明会。本次网上业绩说明会将采用网络远程 的方式举行，投资者可登录"富士莱投资者关系"小程序参与互动交流。为广 泛听取投资者的意见和建议，提前向投资者征集问题，提问通道自发出公告之 日起开放。 出席本次年度业绩说明会的人员有：公司董事长钱祥云先生、董事会秘书 卞爱进先生、财务总监钱桂英女士、独立董事陈忠先生。（如 ...